NCT00680498View on ClinicalTrials.gov

Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

October 31, 2009

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

Ranibizumab

Ranibizumab 0.5 mg

DRUG

Ranibizumab plus Photodynamic therapy

Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)

Trial Locations (1)

60304

Illinois Retina Associates, Oak Park

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Illinois Retina Associates

OTHER